Chicago Partners Investment Group LLC raised its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 293.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 179,962 shares of the medical equipment provider's stock after buying an additional 134,169 shares during the quarter. Chicago Partners Investment Group LLC's holdings in Boston Scientific were worth $8,222,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Covestor Ltd boosted its stake in Boston Scientific by 112.1% in the 3rd quarter. Covestor Ltd now owns 1,968 shares of the medical equipment provider's stock worth $86,000 after purchasing an additional 1,040 shares during the period. Richardson Financial Services Inc. grew its position in Boston Scientific by 6.0% during the 3rd quarter. Richardson Financial Services Inc. now owns 9,735 shares of the medical equipment provider's stock worth $425,000 after purchasing an additional 550 shares in the last quarter. Ascent Group LLC grew its position in Boston Scientific by 29.0% during the 3rd quarter. Ascent Group LLC now owns 48,869 shares of the medical equipment provider's stock worth $2,133,000 after purchasing an additional 10,974 shares in the last quarter. Kelleher Financial Advisors grew its position in Boston Scientific by 1,267.9% during the 3rd quarter. Kelleher Financial Advisors now owns 7,975 shares of the medical equipment provider's stock worth $348,000 after purchasing an additional 7,392 shares in the last quarter. Finally, Focused Wealth Management Inc acquired a new stake in Boston Scientific during the 3rd quarter valued at $222,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.
Boston Scientific Stock Performance
BSX stock opened at $45.73 on Thursday. The company has a quick ratio of 0.74, a current ratio of 1.36 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $66.28 billion, a price-to-earnings ratio of 19.38, a P/E/G ratio of 1.27 and a beta of 0.60. Boston Scientific Corporation has a 12 month low of $39.57 and a 12 month high of $105.65. The firm has a 50 day moving average of $44.47 and a two-hundred day moving average of $56.16.
Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the prior year, the business posted $0.75 EPS. Boston Scientific's quarterly revenue was up 1.4% on a year-over-year basis. As a group, equities analysts anticipate that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
BSX has been the subject of a number of research analyst reports. The Goldman Sachs Group reduced their target price on Boston Scientific from $71.00 to $57.00 and set a "buy" rating for the company in a report on Tuesday, July 14th. Wall Street Zen downgraded Boston Scientific from a "buy" rating to a "hold" rating in a report on Sunday, August 2nd. Royal Bank Of Canada dropped their price target on Boston Scientific from $70.00 to $52.00 and set an "outperform" rating on the stock in a research report on Thursday, October 29th. Weiss Ratings reissued a "sell (d+)" rating on shares of Boston Scientific in a research note on Friday, October 2nd. Finally, Deutsche Bank Aktiengesellschaft set a $48.00 price objective on Boston Scientific and gave the stock a "buy" rating in a research report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Boston Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $61.43.
Read Our Latest Analysis on Boston Scientific
Boston Scientific Profile
(
Free Report)
Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.
Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.